Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: GLPG4716; Drug: Midazolam

• Registration Number: NCT05030857
• Lead Sponsor: Galapagos NV

Brief Summary

The purpose of this study is to determine the effect of the administration of multiple doses of GLPG4716 on the amount of midazolam (MDZ) that gets into the blood when the two drugs are administered together compared to when midazolam is administered alone. Other objectives of this study are to evaluate the safety and tolerability of GLPG4716 when administered with midazolam and assess the amount of GLPG4716 that gets into the blood when administered with midazolam. This study will also assess the effect of food on the amount of GLPG4716 that gets into the blood.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-08-30
• Study First Submitted QC: 2021-08-30
• Study First Posted: 2021-09-01
• Study Start: 2021-09-08
• Status Verified: 2021-11
• Primary Completion: 2021-11-13
• Study Completion: 2021-11-13
• Last Update Submitted: 2021-11-23
• Last Update Posted: 2021-11-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Male or female between 18 and 55 years of age (extremes included), on the date of signing the informed consent form. Female subjects should be of non-childbearing potential.

• A body mass index between 18.0 and 30.0 kg/m2, inclusive.

• Judged to be in good health by the investigator based upon:

  • The results of a medical history
  • Physical examination
  • Vital signs
  • Oxygen saturation
  • 12-lead electrocardiogram
  • Fasting clinical laboratory safety tests. Aspartate aminotransferase and alanine aminotransferase must be no greater than 1.5x upper limit of normal range and total bilirubin no greater than 1x upper limit of normal. Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator.

This list only contains the key inclusion criteria.

Read More

Exclusion Criteria

• Known hypersensitivity to ingredients of GLPG4716 and/or MDZ

• History of a significant allergic reaction to ingredients of GLPG4716 and/or MDZ as determined by the investigator.

• Treatment with any medication including:

  • Over-the-counter and/or prescription medication
  • Dietary supplements
  • Nutraceuticals, vitamins and/or herbal supplements, and hormonal replacement therapy
  • Except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) in the last 2 weeks or 5 half-lives of the drug, whichever is longer, prior to the first dosing.

This list only contains the key exclusion criteria.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
GLPG4716 and Midazolam	Midazolam	-
GLPG4716 and Midazolam	GLPG4716	-

Primary Outcome Measures

Name	Time	Method
Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of MDZ	From Day 1 pre-dose until Day 15	To determine the effect of GLPG4716 on the PK of MDZ
Maximum observed plasma concentration (Cmax) of MDZ	From Day 1 pre-dose until Day 15	To determine the effect of GLPG4716 on the pharmacokinetics (PK) of MDZ

Secondary Outcome Measures

Name	Time	Method
Area under the plasma concentration-time curve over the dosing interval (AUCt) of GLPG4716	From Day 1 pre-dose until Day 15	To assess the effect of food on the PK of GLPG4716.
Cmax of GLPG4716	From Day 1 pre-dose until Day 15	To assess the effect of food on the PK of GLPG4716.
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent (SAEs), and TEAEs leading to treatment discontinuations	From Day 1 through study completion, an average of one month	To evaluate the safety and tolerability of GLPG4716 when co-administered with MDZ

Trial Locations

Locations (1)

Altasciences; 🇨🇦 Montréal, Canada